Stock Track | Travere Therapeutics Soars 16.29% on Impressive Q3 Results and FILSPARI Sales Growth

Stock Track10-31

Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 16.29% on Thursday following the release of its outstanding third-quarter 2025 financial results. The biopharmaceutical company reported a significant increase in revenue and strong sales growth for its key product, FILSPARI, leading to a return to profitability.

Travere's total revenue for Q3 2025 reached $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales grow by an impressive 155% year-over-year to $90.9 million. The company reported a net income of $25.7 million, or $0.28 per share, a substantial improvement from the net loss of $54.8 million in the same quarter last year.

The strong financial performance was attributed to growing adoption of FILSPARI as a foundational therapy for IgA Nephropathy (IgAN). Travere received 731 new patient start forms for FILSPARI during the quarter, indicating continued uptake among new and repeat prescribers. The company is also well-positioned for potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026. Investors appear optimistic about Travere's growth prospects and the expanding market for its key product, driving the stock's significant rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137352116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137352116","market":"us","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 16.29% on Impressive Q3 Results and FILSPARI Sales Growth","media":"Stock Track","content":"<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 16.29% on Thursday following the release of its outstanding third-quarter 2025 financial results. The biopharmaceutical company reported a significant increase in revenue and strong sales growth for its key product, FILSPARI, leading to a return to profitability.</p>\n\n<p>Travere's total revenue for Q3 2025 reached $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales grow by an impressive 155% year-over-year to $90.9 million. The company reported a net income of $25.7 million, or $0.28 per share, a substantial improvement from the net loss of $54.8 million in the same quarter last year.</p>\n\n<p>The strong financial performance was attributed to growing adoption of FILSPARI as a foundational therapy for IgA Nephropathy (IgAN). Travere received 731 new patient start forms for FILSPARI during the quarter, indicating continued uptake among new and repeat prescribers. The company is also well-positioned for potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026. Investors appear optimistic about Travere's growth prospects and the expanding market for its key product, driving the stock's significant rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 16.29% on Impressive Q3 Results and FILSPARI Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 16.29% on Impressive Q3 Results and FILSPARI Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 09:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 16.29% on Thursday following the release of its outstanding third-quarter 2025 financial results. The biopharmaceutical company reported a significant increase in revenue and strong sales growth for its key product, FILSPARI, leading to a return to profitability.</p>\n\n<p>Travere's total revenue for Q3 2025 reached $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales grow by an impressive 155% year-over-year to $90.9 million. The company reported a net income of $25.7 million, or $0.28 per share, a substantial improvement from the net loss of $54.8 million in the same quarter last year.</p>\n\n<p>The strong financial performance was attributed to growing adoption of FILSPARI as a foundational therapy for IgA Nephropathy (IgAN). Travere received 731 new patient start forms for FILSPARI during the quarter, indicating continued uptake among new and repeat prescribers. The company is also well-positioned for potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026. Investors appear optimistic about Travere's growth prospects and the expanding market for its key product, driving the stock's significant rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1137352116","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137352116","pubTimestamp":1761873883,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 16.29% on Thursday following the release of its outstanding third-quarter 2025 financial results. The biopharmaceutical company reported a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"个股追踪|Travere Therapeutics因令人印象深刻的第三季度业绩和FILSPARI销售增长而飙升16.29%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 16.29% on Thursday following the release of its outstanding third-quarter 2025 financial results. The biopharmaceutical company reported a significant increase in revenue and strong sales growth for its key product, FILSPARI, leading to a return to profitability.\nTravere's total revenue for Q3 2025 reached $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales grow by an impressive 155% year-over-year to $90.9 million. The company reported a net income of $25.7 million, or $0.28 per share, a substantial improvement from the net loss of $54.8 million in the same quarter last year.\nThe strong financial performance was attributed to growing adoption of FILSPARI as a foundational therapy for IgA Nephropathy (IgAN). Travere received 731 new patient start forms for FILSPARI during the quarter, indicating continued uptake among new and repeat prescribers. The company is also well-positioned for potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026. Investors appear optimistic about Travere's growth prospects and the expanding market for its key product, driving the stock's significant rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137352116","isCrawlerRequest":true}